Pulse Biosciences, Inc. (PLSE) · Sep 15, 2026 · Share issuance

Pulse Biosciences replaces nearly exhausted ATM with new $85M equity facility

$85M equity facility — New ATM up to $85M; ~$68.8M already sold under prior $75M Mizuho ATM

Pulse adds $85M of fresh ATM capacity after selling $68.8M under its prior Mizuho program—more runway, but further dilution remains possible.

Pulse is a clinical-stage bioelectric-medicine company using Nano-Pulse Stimulation to advance nPulse systems in electrophysiology and soft-tissue ablation; its 2026 plan calls for completing NANOPULSE-AF IDE enrollment by early Q4.

The filing mainly preserves financing access, rather than delivering cash today. Pulse authorized a new Mizuho at-the-market program for up to $85 million. The company is not required to sell any shares, so this is borrowing capacity in equity form—not a committed $85 million financing.

ItemAmount / statusFiling reference
New Mizuho ATM capacityUp to $85.0MSales Agreement
Prior Mizuho ATM authorizationUp to $75.0MAugust 2026 Sales Agreement
Prior Mizuho shares sold through Sept. 141,379,925 sharesPrior offering disclosure
Prior Mizuho proceedsApproximately $68.8MPrior offering disclosure
TD Cowen ATM capacity left at terminationUp to $1.0M unsoldTD Cowen Distribution Agreement
Sales-agent commissionUp to 3.0%Sales Agreement

The new facility is an expansion of an already-active funding strategy, not a surprise pivot. Pulse had already sold approximately $68.8 million of the prior $75 million Mizuho authorization by September 14. Replacing that nearly exhausted authorization with another $85 million makes the direction—funding ongoing clinical and product development—largely known; the new information is the size of the replacement capacity.

The business benefit is flexibility; the cost is potential dilution. The program lets Pulse raise capital opportunistically as it advances cardiac and soft-tissue programs, but every sale increases the share count and can fund operations only by issuing equity. The filing does not say that any of the new shares have been sold, and it provides no updated cash runway, so it improves optionality without yet changing the company’s operating resources.

Terminating the TD Cowen program is administrative consolidation, not a separate strategic event. Only up to $1.0 million remained available under that agreement when it was ended, while the new Mizuho program becomes the meaningful source of future ATM capacity.

Bottom line: Pulse has secured a larger equity funding channel to support its clinical-stage buildout, but no new cash was raised in this filing. It is modestly supportive for liquidity flexibility and equally clear about the continuing dilution and capital-need overhang.

What to watch next

NANOPULSE-AF IDE enrollment target, early Q4 2026

Original filing on SEC EDGAR

More Pulse Biosciences, Inc. news

Pulse Biosciences replaces nearly exhausted ATM with new $85M equity facility | PLSE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.